Status:
COMPLETED
Metabolomics of Aging: Sub-study of the Healthy Elderly Active Longevity (HEAL) Study
Lead Sponsor:
Scripps Translational Science Institute
Conditions:
Healthy
Eligibility:
MALE
80-85 years
Brief Summary
This research is being done to learn more about healthy aging. We hope to learn which bodily processes or functions are important for the elderly to maintain good health. Metabolites (for example, glu...
Detailed Description
The HEAL study criteria includes subjects who are 80 years of age and older who have not experienced a chronic condition. This sub-study will use plasma samples of up to 100 HEAL subjects to compare t...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Age 80 to 85 years
- Gender: Male
- Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study
- Eligible for Blood draw
- Be reliable, cooperative and willing to comply with all protocol-specified procedures.
- Able to understand and grant informed consent
- Be healthy or have mild medical conditions that may be associated with the normal aging process, including:
- Hypertension, well controlled with no more than 3 medications
- Osteoporosis or Osteopenia
- Osteoarthritis
- Benign Prostatic Hypertrophy
- Cataracts, Glaucoma or Macular Degeneration
- Dyslipidemia
- Hypothyroidism
- Pre-Diabetes/Impaired Fasting Glucose (fasting blood glucose 100-126 mg/dL, if known)
- Basal or Squamous Cell Carcinoma
- Individuals will be excluded if ANY of the following conditions apply:
- EXCLUSION CRITERIA
- Less than 80 years of age or greater than 85 years of age
- Gender: Female
- Currently undergoing treatment with any investigational agents or devices within 30 preceding enrollment in this study.
- Self-reported history or current diagnosis of significant chronic conditions including"
- Any Cancer (including polycythemia; excluding basal or squamous cell carcinoma
- Coronary Artery Disease, Myocardial Infarction
- Stroke or Transient Ischemic Attack (TIA)
- Deep Vein Thrombosis or Pulmonary Embolism
- Chronis Renal Disease or Hemodialysis
- Significant Auto-Immune or Inflammatory conditions such as Rheumatoid Arthritis, Lupus, Crohn's Disease, etc.
- Alzheimer's or Parkinson's Disease
- Diabetes (Hemoglobin A1C \> 6.5% or fasting glucose \> 126 mg/dL or is treated with insulin or oral diabetic medication
- Aortic or Cerebral Aneurysm
- Currently taking any of the following medications on a regular basis:
- Chemotherapeutic agents (ex. Tamoxifen, Doxorubicin, Mitoxantrone, bleomycin
- Anti-platelet or anticoagulant agents, not including Aspirin (ex. Clopidogrel/Plavix, Dipyridamole/Aggrenox/Persantine, Ticlopidine/Ticlid, Warfarin/Coumadin, Plasugrel, etc.)
- Cholinesterase inhibitor for Alzheimer's disease (i.e. Donzepril/Aricept)
- Insulin or oral diabetic medication
- Individual has a significant medical condition which, in the investigator's opinion, may interfere with the individual's optimal participation in the study or would potentially confound interpretation of the individual's phenotype.
Exclusion
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01209884
Start Date
February 1 2010
End Date
December 1 2012
Last Update
January 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Translational Science Institute
La Jolla, California, United States, 92037